Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14180756 | 0.91 | CNR1 (0.46) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180963 | 0.90 | CNR1 (0.48) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180961 | 0.90 | CNR1 (0.48) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180939 | 0.88 | CNR1 (0.47) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180951 | 0.87 | CNR1 (0.48) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180964 | 0.87 | CNR1 (0.46) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180952 | 0.86 | CNR1 (0.47) | CNR1SMN1; SMN2LMNAPOLBMAPT | |
| SCHEMBL4804647 | 0.85 | CNR1 (0.47) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4804639 | 0.85 | CNR1 (0.47) | CNR1GPR119RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14180949 | 0.85 | CNR1 (0.47) | CNR1GPR119RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648896-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005014596-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | claimed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063761-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BROSTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | CNR1 1/4885GPR119 42/4885RAB9A 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.